Investor Presentaiton
LILLY SELECT NME AND NILEX PIPELINE
August 4, 2023
Lilly
UCENPRUBART
(CD200R MAB AGONIST)
Immunology
RETATRUTIDE
Diabetes
GBA1 GENE THERAPY
Gaucher Disease Type 1
SSTR4 AGONIST
Pain
RELAXIN-LA
Heart Failure
TIRZEPATIDE
NASH
PIRTOBRUTINIB
B-Cell Malignancies
GBA1 GENE THERAPY
Gaucher Disease Type 2
SOLBINSIRAN
RET INHIBITOR II
Cancer
RIPK1 INHIBITOR
Immunology
SARM1 INHIBITOR
Neurodegeneration
NRG4 AGONIST
Heart Failure
NISOTIROSTIDE
(PYY ANALOG)
Diabetes
KRAS G12C II
Cancer
KV1.3 ANTAGONIST
Immunology
PI3K SELECTIVE
Cancer
PNPLA3 siRNA
NASH
CVD
NOT DISCLOSED
Diabetes
NOT DISCLOSED
Pain
P2X7 INHIBITOR
Pain
MAZDUTIDE
Obesity
MUVALAPLIN
CVD
LEPODISIRAN
GIPR AGONIST LA
Diabetes
GIPR AGONIST LA II
Diabetes
CD19 ANTIBODY
Immunology
DACRA QW II
Obesity
AMYLIN AGONIST LA
Obesity
APOC3 siRNA
CVD
PHASE 1
IDH1/2 INHIBITOR
Cancer
GIP/GLP COAGONIST
PEPTIDE Diabetes
GITR ANTAGONIST
Immunology
FGFR3 SELECTIVE
Cancer
AT2R ANTAGONIST
Pain
(LPA siRNA)
CVD
GBA1 GENE THERAPY
Parkinson's Disease
BTLA MAB AGONIST
Systemic Lupus Erythematosus
PERESOLIMAB
Rheumatoid Arthritis
O-GLCNACASE INH
Alzheimer's Disease
MEVIDALEN
Symptomatic LBD
GRN GENE THERAPY
Frontotemporal Dementia
ELTREKIBART
Hidradenitis Suppurativa
PHASE 2
ORFORGLIPRON
Diabetes
TIRZEPATIDE
MMO
TIRZEPATIDE
Obstructive Sleep Apnea
NME
NILEX
TIRZEPATIDE
Heart Failure pEF
*
Commercial
Collaboration
TIRZEPATIDE
CV Outcomes
SELPERCATINIB
Adjuvant RET+ NSCLC
PIRTOBRUTINIB
R/R CLL Monotherapy
PIRTOBRUTINIB
1L CLL Monotherapy
IMLUNESTRANT
Adjuvant Breast Cancer
DONANEMAB
Preclinical Alzheimer's
Disease
ABEMACICLIB
Hormone Sensitive
Prostate Cancer
RETATRUTIDE
Obesity
REMTERNETUG
Alzheimer's Disease
IMLUNESTRANT
ER+ HER2-mBC
SELPERCATINIB
1L Med Thyroid Cancer
PIRTOBRUTINIB
R/R MCL Monotherapy
PIRTOBRUTINIB
R/R CLL Combination
MIRIKIZUMAB
Crohn's Disease
EMPAGLIFLOZIN*
Post MI
ABEMACICLIB
MBC Sequencing
ABEMACICLIB
Castrate Resistant
Prostate Cancer
ORFORGLIPRON
Obesity
INSULIN EFSITORA ALFA
Diabetes
PHASE 3
LEGEND
MOVEMENT SINCE
April 24, 2023
ADDITION or
MILESTONE ACHIEVED
REMOVAL
Phase 3 in China with Innovent for T2DM and Obesity
PIRTOBRUTINIB
CLL Accelerated Approval
TIRZEPATIDE
Obesity
LEBRIKIZUMAB
Atopic Dermatitis
DONANEMAB
Alzheimer's Disease
REG REVIEW
EMPAGLIFLOZIN*
Chronic Kidney Disease
APPROVED
Not for promotional use
2023 Q2 EARNINGS
18View entire presentation